Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals develops clinical-stage therapies for addiction and related disorders, with its lead investigational product candidate, AD04, focused on alcohol use disorder in heavy drinking patients. News about ADIL commonly centers on AD04 clinical-development planning, FDA-related regulatory discussions, precision-medicine positioning, intellectual property filings, manufacturing and technical-transfer work, and potential commercial pathways for the program.
Company updates also cover financial results, cash runway commentary, Nasdaq listing compliance, and governance or capital-structure actions tied to its public-company status. The recurring business context is a single-segment biopharmaceutical developer advancing a genetically targeted serotonin-3 receptor antagonist approach for alcohol use disorder.
Adial (NASDAQ: ADIL) applauded the Feb. 4, 2026 federal appropriations bill that includes a Congressional directive titled “Alternative Clinical Trial Endpoints for Substance Use Disorders.” The law directs the FDA and NIDA to collaborate on non‑abstinence endpoints—such as reduced cravings or disorder severity—that demonstrate meaningful clinical benefit.
Adial says the directive aligns with NIAAA’s updated recovery definition and could strengthen the regulatory pathway for its lead investigational therapy, AD04, which targets Alcohol Use Disorder using a precision medicine approach.
Adial Pharmaceuticals (NASDAQ: ADIL) will effect a 1-for-25 reverse stock split effective Feb 5, 2026 at 11:59 p.m. ET, reducing outstanding common shares from ~27.8 million to ~1.1 million and retaining the ADIL ticker. Common stock will trade on a split-adjusted basis on Feb 6, 2026.
The split is intended to restore compliance with Nasdaq's $1.00 minimum bid price, provide a new CUSIP 00688A304, adjust outstanding equity awards and warrants proportionally, and cash out fractional shares based on the 10-day average closing price preceding effectiveness.
Adial (NASDAQ: ADIL) announced publication of an international PCT patent application for AD04 on January 14, 2026. AD04 is described as the company’s lead investigational genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder (AUD) in heavy drinking patients (defined in the release as < 10 drinks/drinking day). The company said the patent, if granted, is expected to protect Adial’s core assets through at least 2045. Management attributed the application to an extensive examination of clinical data after hiring new patent counsel and said the filing was originally made in July 2024.
Adial Pharmaceuticals (NASDAQ: ADIL) announced a warrant inducement agreement with an existing healthcare institutional investor to support immediate exercise of existing Series C-1 and Series E warrants at a reduced exercise price of $0.31. The exercises could purchase up to 9,215,675 shares of common stock and generate approximately $2.86 million in gross proceeds before fees and expenses.
In a private placement, the investor will receive new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31, exercisable after shareholder approval and expiring 24 months after the Approval Date. Closing is expected on or about December 1, 2025, subject to customary conditions.
Adial Pharmaceuticals (NASDAQ: ADIL) reported Q3 2025 results and a business update on Nov 14, 2025. Key regulatory progress included a successful End of Phase 2 (EOP2) meeting with FDA providing guidance on an adaptive Phase 3 design, and confirmation that the company's cheek swab Genomind test is a Non-Significant Risk (NSR) for use in Phase 3. The company targets biomarker-positive (AG+) AUD patients, citing an AG+ prevalence of ~14%. Intellectual property work includes a provisional patent update filed July 9, 2025, expected to protect core assets through 2045. Financially, cash was $4.6M at Sept 30, 2025 (down from $5.9M), the company expects funding into Q2 2026, R&D expense fell ~50% YoY, and net loss was $1.8M for Q3 2025.
Adial Pharmaceuticals (NASDAQ: ADIL) announced that CEO Cary Claiborne was a featured guest on The Big Biz Show. The episode aired on October 15, 2025 on cable networks including Fox Business, NBCUniversal and Time Warner Cable, on streaming services such as Roku, Apple TV and fire TV, and on radio via The Biz Talk Radio Network, Armed Forces Radio and iHeart Media reaching 175 countries.
The program is also available on the company website at www.adial.com/newsroom.
Adial Pharmaceuticals (NASDAQ: ADIL) announced completion of analytical validation for a cheek swab collection method and companion gene test developed with Genomind to identify serotonergic SNPs (HTR3A, HTR3B, SLC6A4) for AD04 clinical and future commercial use.
Genomind validated accuracy, reproducibility, and robustness across diverse samples and operators, reporting 100% concordance. The test detects long/short SLC6A4 promoter forms. FDA confirmed use of the test in Phase 3 is Non‑Significant Risk (NSR) and an IDE is not required. The AG+ biomarker is present in ~14% of the population. Adial also noted a new patent filing for AD04 expected to extend exclusivity to 2045.
Adial Pharmaceuticals (NASDAQ: ADIL) has received positive feedback from the FDA following their End-of-Phase 2 (EOP2) meeting regarding AD04, their lead drug candidate for Alcohol Use Disorder (AUD). The FDA has aligned with Adial's proposed Phase 3 adaptive trial design for AD04, a serotonin-3 receptor antagonist targeting AUD patients with specific genotypes.
Key elements approved include the biomarker-positive patient strategy, targeting the AG+ biomarker present in approximately 14% of the population. The FDA confirmed primary efficacy endpoints focusing on zero heavy drinking days during months 5 and 6 of the observation period. The agency also supported Adial's plans for interim analyses and provided guidance on statistical analysis plans.
The company views this regulatory milestone as pivotal for advancing toward Phase 3 trials and potentially becoming the first genetically targeted therapy for AUD. This development, combined with their recent patent filing potentially extending market exclusivity to 2045, positions AD04 as a significant commercial opportunity.
Adial Pharmaceuticals (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on addiction treatment therapies, has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The extension follows the expiration of an initial 180-day compliance period on September 1, 2025.
The company now has until March 2, 2026 to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive business days. The notification does not immediately affect ADIL's listing status, and shares will continue trading on the Nasdaq Capital Market.
Adial Pharmaceuticals (NASDAQ: ADIL) welcomes recent U.S. Senate legislative support for expanding clinical trial endpoints beyond abstinence in substance use disorder treatments, particularly for Alcohol Use Disorder (AUD). The Senate Appropriations Committee passed a report with a bipartisan 26-3 vote, encouraging the FDA and NIDA to consider alternative endpoints such as reduced cravings and decreased disorder severity.
This development aligns with Adial's clinical strategy for AD04, their lead investigational drug, a serotonin-3 receptor antagonist designed to treat AUD in patients with specific genotypes. The legislative support validates the company's approach of focusing on reducing alcohol intake and cravings rather than complete abstinence.